JP2016521754A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521754A5 JP2016521754A5 JP2016519675A JP2016519675A JP2016521754A5 JP 2016521754 A5 JP2016521754 A5 JP 2016521754A5 JP 2016519675 A JP2016519675 A JP 2016519675A JP 2016519675 A JP2016519675 A JP 2016519675A JP 2016521754 A5 JP2016521754 A5 JP 2016521754A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- difficile
- use according
- days
- toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000193163 Clostridioides difficile Species 0.000 claims 16
- 230000028993 immune response Effects 0.000 claims 7
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 5
- 101710182223 Toxin B Proteins 0.000 claims 5
- 101710182532 Toxin a Proteins 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 241000193403 Clostridium Species 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000002045 lasting effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000002346 musculoskeletal system Anatomy 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361835246P | 2013-06-14 | 2013-06-14 | |
| US61/835,246 | 2013-06-14 | ||
| PCT/US2014/042298 WO2014201346A1 (en) | 2013-06-14 | 2014-06-13 | Compositions and methods of immunizing against c. difficile |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016521754A JP2016521754A (ja) | 2016-07-25 |
| JP2016521754A5 true JP2016521754A5 (enExample) | 2017-07-27 |
| JP6691477B2 JP6691477B2 (ja) | 2020-04-28 |
Family
ID=51168412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016519675A Active JP6691477B2 (ja) | 2013-06-14 | 2014-06-13 | クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9730994B2 (enExample) |
| EP (1) | EP3007724B1 (enExample) |
| JP (1) | JP6691477B2 (enExample) |
| KR (1) | KR20160020543A (enExample) |
| CN (1) | CN105611942A (enExample) |
| AU (1) | AU2014277981B2 (enExample) |
| BR (1) | BR112015031088A2 (enExample) |
| CA (1) | CA2915279A1 (enExample) |
| MX (1) | MX2015017257A (enExample) |
| SG (1) | SG11201510166YA (enExample) |
| TW (1) | TWI648063B (enExample) |
| WO (1) | WO2014201346A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2969952T3 (es) | 2011-04-22 | 2024-05-23 | Wyeth Llc | Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| CN105611942A (zh) | 2013-06-14 | 2016-05-25 | 圣诺菲·帕斯图尔公司 | 针对艰难梭菌免疫的组合物和方法 |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| WO2019064115A1 (en) * | 2017-09-28 | 2019-04-04 | Pfizer Inc. | COMPOSITIONS AND METHODS FOR GENERATING A DIFFICULT CLOSTRIDIUM IMMUNE RESPONSE |
| WO2021255690A2 (en) | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5071759A (en) | 1986-05-30 | 1991-12-10 | The United States Of America As Represented By The Secretary Of The Army | Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B |
| US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| EP1024826B1 (en) | 1997-10-20 | 2005-03-16 | Acambis, Inc. | Passive immunization against clostridium difficile disease |
| EP2198007B1 (en) * | 2007-09-14 | 2017-10-25 | Sanofi Pasteur Biologics, LLC | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| ES2969952T3 (es) | 2011-04-22 | 2024-05-23 | Wyeth Llc | Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos |
| AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| GB201206070D0 (en) | 2012-04-04 | 2012-05-16 | Health Prot Agency | Clostridium difficile antigens |
| JP2016516721A (ja) | 2013-03-15 | 2016-06-09 | サノフィ パストゥール インコーポレイテッド | トキソイド、組成物および関連方法 |
| US20160030542A1 (en) | 2013-03-15 | 2016-02-04 | Sanofi Pasteur, Inc. | Toxoid, Compositions and Related Methods |
| CN105611942A (zh) | 2013-06-14 | 2016-05-25 | 圣诺菲·帕斯图尔公司 | 针对艰难梭菌免疫的组合物和方法 |
-
2014
- 2014-06-13 CN CN201480044768.7A patent/CN105611942A/zh active Pending
- 2014-06-13 KR KR1020167001130A patent/KR20160020543A/ko not_active Ceased
- 2014-06-13 MX MX2015017257A patent/MX2015017257A/es unknown
- 2014-06-13 EP EP14737429.2A patent/EP3007724B1/en active Active
- 2014-06-13 CA CA2915279A patent/CA2915279A1/en not_active Abandoned
- 2014-06-13 AU AU2014277981A patent/AU2014277981B2/en not_active Ceased
- 2014-06-13 BR BR112015031088A patent/BR112015031088A2/pt not_active Application Discontinuation
- 2014-06-13 US US14/897,870 patent/US9730994B2/en active Active
- 2014-06-13 SG SG11201510166YA patent/SG11201510166YA/en unknown
- 2014-06-13 WO PCT/US2014/042298 patent/WO2014201346A1/en not_active Ceased
- 2014-06-13 JP JP2016519675A patent/JP6691477B2/ja active Active
- 2014-06-16 TW TW103120772A patent/TWI648063B/zh not_active IP Right Cessation
-
2017
- 2017-07-10 US US15/645,057 patent/US20170304423A1/en not_active Abandoned
-
2019
- 2019-10-21 US US16/658,278 patent/US20200113991A1/en not_active Abandoned
-
2021
- 2021-01-08 US US17/144,486 patent/US11419930B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015057451A5 (enExample) | ||
| JP2016540785A5 (enExample) | ||
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| JP2016540021A5 (enExample) | ||
| JP2018531984A5 (enExample) | ||
| JP2012506411A5 (enExample) | ||
| HK1216393A1 (zh) | 用於治疗胃肠痉挛的方法 | |
| JP2015523407A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| JP2015520196A5 (enExample) | ||
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| JP2016027060A5 (enExample) | ||
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| HK1218865A1 (zh) | 用於降低多发性硬化症中丘脑损伤的拉喹莫德 | |
| JP2012021028A5 (enExample) | ||
| JP2014507475A5 (enExample) | ||
| MX2015017257A (es) | Composiciones y metodos de inmunizar contra clostridium difficile. | |
| HRP20230070T1 (hr) | Tasimelteon za liječenje smith-magenis sindroma | |
| JP2016505050A5 (enExample) | ||
| CN104337916A (zh) | 一种手脚冰凉及脚气的中药药剂 | |
| JP2017061488A5 (enExample) | ||
| JP2019507786A5 (enExample) | ||
| JP2020536098A5 (enExample) | ||
| HK1225972A1 (zh) | 利用拉喹莫德来延缓亨廷顿氏病的进展 | |
| JP2016538288A5 (enExample) |